1-20 of 36
Paolo Strati
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Clinical Trials & Observations
Philip A. Thompson, Jaya Srivastava, Christine Peterson, Paolo Strati, Jeffrey L. Jorgensen, Tyler Hether, Michael J. Keating, Susan M. O’Brien, Alessandra Ferrajoli, Jan A. Burger, Zeev Estrov, Nitin Jain, William G. Wierda
Blood (2019) 134 (22): 1951–1959.
DOI: https://doi.org/10.1182/blood.2019001077
Published: 2019
Includes: Supplemental data
Journal Articles

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Nathan H Fowler, MD, Loretta J. Nastoupil, MD MSc, Collin Chin, MBBS, Paolo Strati, MD, Fredrick B. Hagemeister, MD, Luis E. Fayad, MD, Jason R. Westin, MD, Sheryl G Forbes, Janine Arafat, Lei Feng, MS, Ranjit Nair, MBBS,MD, Raphael E Steiner, MD, Felipe Samaniego, MD, Sattva S Neelapu, MD
Blood (2019) 134 (Supplement_1): 348.
DOI: https://doi.org/10.1182/blood-2019-131045
Published: 2019
Journal Articles

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Paolo Strati, MD, Sudhakar Tummala, Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Luis Fayad, MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, F. B. Hagemeister, MD, Hun Ju Lee, MD, Swaminathan P. Iyer, MD, Ranjit Nair, MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Raphael Eric Steiner, MD, Michael L. Wang, MD, Chelsea Camille Pinnix, MD PhD, Sherry Adkins, ANP, Catherine M. Claussen, MS, Charles Martinez, Misha Hawkins, Nicole Johnson, Shirley George, Sattva S Neelapu, MD, Linda Chi, MD
Blood (2019) 134 (Supplement_1): 765.
DOI: https://doi.org/10.1182/blood-2019-125769
Published: 2019
Journal Articles

Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma

Paolo Strati, MD, Ralph J. Johnson, PhD, Sheryl G Forbes, Loretta J. Nastoupil, MD MSc, Felipe Samaniego, MD, Eric Davis, MD, Michael R Green, PhD, Luis Fayad, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Michael L. Wang, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD
Blood (2019) 134 (Supplement_1): 1533.
DOI: https://doi.org/10.1182/blood-2019-129311
Published: 2019
Journal Articles

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Chelsea C Pinnix, MD PhD, Jillian R Gunther, MD PhD, Bouthaina S. Dabaja, MD, Sherry Adkins, ANP, Misha Hawkins, Jason R. Westin, MD, Luis Fayad, MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, Fredrick B. Hagemeister, MD, Swaminathan P. Iyer, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Paolo Strati, MD, Simrit Parmar, MBBS, Felipe Samaniego, MD, Michael Wang, MD, Sattva S Neelapu, MD, Loretta J. Nastoupil, MD MSc
Blood (2019) 134 (Supplement_1): 1609.
DOI: https://doi.org/10.1182/blood-2019-131499
Published: 2019
Journal Articles

Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse

Dahlia Sano, MD, Paolo Strati, MD, Pedro Alcedo, MD, V Ahalya Rao, MD, Prachee Singh, Roberto N. Miranda, MD, Jillian R Gunther, MD PhD, Chelsea Camille Pinnix, MD PhD, Bouthaina S. Dabaja, MD, Feng Lei, MS, Hun Ju Lee, MD, Raphael E Steiner, MD
Blood (2019) 134 (Supplement_1): 5291.
DOI: https://doi.org/10.1182/blood-2019-125980
Published: 2019
Journal Articles

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection

Clinical Trials & Observations
Paolo Strati, Loretta J. Nastoupil, Luis E. Fayad, Felipe Samaniego, Sherry Adkins, Sattva S. Neelapu
Blood (2019) 133 (26): 2800–2802.
DOI: https://doi.org/10.1182/blood.2019000888
Published: 2019
Journal Articles

Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Paolo Strati, MD, Mariela Sivina, PhD, Ekaterina Kim, PhD, Michael J. Keating, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, MD, Zeev E. Estrov, MD, Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD
Blood (2018) 132 (Supplement 1): 1873.
DOI: https://doi.org/10.1182/blood-2018-99-111044
Published: 2018
Journal Articles

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Paolo Strati, MD, Koichi Takahashi, MD, Michael J. Keating, MD, Philip A. Thompson, MBBS, Christina Hinojosa, Diana Rodriguez, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, William G. Wierda, MD PhD, Andrew Futreal, PhD, Alessandra Ferrajoli, MD
Blood (2018) 132 (Supplement 1): 295.
DOI: https://doi.org/10.1182/blood-2018-99-111488
Published: 2018
Journal Articles

Undetectable-Minimal Residual Disease (U-MRD6) (10 -6 sensitivity) Is Associated with Best Progression-Free Survival for Patients Who Achieve Bone Marrow Undetectable MRD4 (10 -4 sensitivity) with First-Line FCR

Philip A. Thompson, MBBS, Jaya Srivastava, Paolo Strati, MD, Jeffrey L. Jorgensen, MD PhD, Joyce Breaker, Tyler Hether, Michael J Keating, MBBS, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Zeev E. Estrov, MD, Nitin Jain, MD, William G. Wierda, MD PhD
Blood (2018) 132 (Supplement 1): 3137.
DOI: https://doi.org/10.1182/blood-2018-99-117864
Published: 2018
Journal Articles

Ruxolitinib Therapy Improves Renal Function in Patients with Primary Myelofibrosis

Paolo Strati, MD, Maen Abdelrahim, Umut Selamet, Valda Page, Sherry A. Pierce, BSN, BA, Srdan Verstovsek, MD PhD, Ala Abudayyeh
Blood (2018) 132 (Supplement 1): 4296.
DOI: https://doi.org/10.1182/blood-2018-99-109871
Published: 2018
Journal Articles

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

Clinical Trials & Observations
Koichi Takahashi, Boyu Hu, Feng Wang, Yuanqing Yan, Ekaterina Kim, Candida Vitale, Keyur P. Patel, Paolo Strati, Curtis Gumbs, Latasha Little, Samantha Tippen, Xingzhi Song, Jianhua Zhang, Nitin Jain, Philip Thompson, Guillermo Garcia-Manero, Hagop Kantarjian, Zeev Estrov, Kim-Anh Do, Michael Keating, Jan A. Burger, William G. Wierda, P. Andrew Futreal, Alessandra Ferrajoli
Blood (2018) 131 (16): 1820–1832.
DOI: https://doi.org/10.1182/blood-2017-11-817296
Published: 2018
Includes: Supplemental data
Journal Articles

Sustained Long-Lasting Responses after Lenalidomide Discontinuation in Patients with Chronic Lymphocytic Leukemia

Paolo Strati, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Susan M. O'Brien, MD, Katy Rezvani, MD PhD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Christina Hinojosa, Michael J. Keating, MD, Zeev Estrov, MD
Blood (2017) 130 (Supplement 1): 3024.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3024.3024
Published: 2017
Journal Articles

A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas

Paolo Strati, MD, Yasuhiro Oki, MD, Luis E. Fayad, Loretta Nastoupil, MD, Nathan H. Fowler, MD, F. B. Hagemeister, MD, Larry W Kwak, MDPhD, Hun Ju Lee, MD, Michael Wang, MD, Jason R. Westin, MD, Charnelle Ruben, Emily Wesson, NP, Michelle A. Fanale, MD
Blood (2017) 130 (Supplement 1): 4074.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4074.4074
Published: 2017
Journal Articles

Immature Platelet Fraction Is Associated with JAK2 V617F Mutation and Features of Advanced Disease in Myelofibrosis

Paolo Strati, MD, Pritviraj Bose, Katie Gaw, Lingsha Zhou, Sherry Pierce, BSN, BA, Julie Huynh-Lu, Carlos E. Bueso-Ramos, MD PhD, Srdan Verstovsek, MD PhD
Blood (2016) 128 (22): 1933.
DOI: https://doi.org/10.1182/blood.V128.22.1933.1933
Published: 2016
Journal Articles

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Paolo Strati, MD, Philip A Thompson, MBBS, Michael Keating, MBBS, Christina Hinojosa, Diana Rodriguez, Xuemei Wang, MS, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, William G. Wierda, MD PhD, Hagop M. Kantarjian, MD, Susan Obrien, MD BA, Alessandra Ferrajoli, MD
Blood (2016) 128 (22): 4389.
DOI: https://doi.org/10.1182/blood.V128.22.4389.4389
Published: 2016
Journal Articles

Solid Tumors in Patients with Chronic Lymphocytic Leukemia Who Received Frontline Lenalidomide Therapy: Distribution and Clinical Outcomes

Ahmad Alhuraiji, MD MRCP, Lorenzo Falchi, MD, Michael Keating, MBBS, Zeev Estrov, MD, Paolo Strati, MD, William Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Alessandra Ferrajoli, MD
Blood (2016) 128 (22): 5573.
DOI: https://doi.org/10.1182/blood.V128.22.5573.5573
Published: 2016
Journal Articles

LDH Levels Predict Progression-Free Survival in Treatment-NaÏVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia

Francesco Autore, MD, Paolo Strati, MD, Idanna Innocenti, MD, Francesco Corrente, Livio Trentin, MD, Agostino Cortelezzi, MD, Marta Coscia, MD PhD, Alessandro Gozzetti, MD, Massimo Gentile, MD, Fortunato Morabito, MD, Giovanni D'Arena, MD, Roberta Murru, MD, Donatella Iolanda Vincelli, MD, Gianluigi Reda, MD, Candida Vitale, MD, Alessandra Ferrajoli, MD, Luca Laurenti
Blood (2016) 128 (22): 3211.
DOI: https://doi.org/10.1182/blood.V128.22.3211.3211
Published: 2016
Journal Articles

Early Achievement of MRD-Negativity in IGHV-M utated ( IGHV-M ) Patients Portends Highly Favorable Outcomes after First-Line Treatment of CLL with Fludarabine, Cyclophosphamide and Rituximab (FCR). Serial Monitoring for Minimal Residual Disease (MRD) in Blood after Achieving MRD-Negativity Predicts Subsequent Clinical Relapse

Philip A Thompson, MBBS, Paolo Strati, MD, Michael Keating, MBBS, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Jan A Burger, MD PhD, Jeffrey L. Jorgensen, MD PhD, Stefan Faderl, MD, Zeev Estrov, MD, Nitin Jain, MD, Tapan Kadia, MD, Gautam Borthakur, MBBS, Courtney D. DiNardo, MD MSCE, Naval G. Daver, MD, Elias J. Jabbour, MD, William G Wierda, MD PhD
Blood (2016) 128 (22): 232.
DOI: https://doi.org/10.1182/blood.V128.22.232.232
Published: 2016
Journal Articles

Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis

Clinical Trials & Observations
Sameer A. Parikh, Paolo Strati, Mazie Tsang, Colin P. West, Tait D. Shanafelt
Blood (2016) 127 (14): 1752–1760.
DOI: https://doi.org/10.1182/blood-2015-10-620864
Published: 2016